New health and biological research findings
最新健康與生物研究發現
更新於: 2026年9月21日 上午04:30
As of September 2026, the intersection of artificial intelligence and genomic research has triggered a revolution in personalized medicine.
截至2026年9月，人工智慧與基因組學研究的交集已在個人化醫療領域引發了一場革命。
Recent findings are fundamentally changing our understanding of human health.
近期的研究發現正在從根本上改變我們對人類健康的理解。《
Studies published in Science highlight a critical transition in the brain between ages 50 and 75, where inflammatory immune cells begin to compromise the blood-brain barrier, providing new clues about neurodegeneration.
科學》雜誌發表的研究強調了50歲至75歲之間大腦的一個關鍵轉折點，此時發炎性免疫細胞開始破壞血腦屏障，為神經退化提供了新線索。
Simultaneously, research from Washington University suggests that 'biological age acceleration'—where the body appears older than its chronological age—is linked to the alarming rise of early-onset cancers in adults under 55.
與此同時，華盛頓大學的研究指出，「生物年齡加速」——即身體看起來比實際年齡更老——與55歲以下成年人早發性癌症的驚人增長有關。
In oncology, scientists at Wake Forest University have identified the SIRPα protein as a key culprit in how breast cancer cells evade immune defenses.
在腫瘤學方面，維克森林大學的科學家已鑑定出SIRPα蛋白是乳癌細胞逃避免疫防禦的關鍵罪魁禍首。
Furthermore, discoveries regarding caspases reveal how cells might regenerate tissues or, conversely, survive cancer treatments.
此外，關於胱天蛋白酶的發現揭示了細胞如何再生組織，或者相反地，如何在癌症治療中存活下來。
The industry is shifting from one-size-fits-all treatments toward precision medicine.
產業正從「一體適用」的治療轉向精準醫療。
With AI now acting as an agentic partner in drug development, the focus is firmly on clinical evidence and human-relevant outcomes, marking a transformative era for global health.
隨著人工智慧現在成為藥物開發中的自主合作夥伴，重點已堅定地放在臨床證據和人類相關的結果上，標誌著全球健康進入了一個轉型時代。
